Innovative Cellular Therapeutics Holdings Ltd 3
3 · Lyell Immunopharma, Inc. · Filed Jun 18, 2026
Insider Transaction Report
Form 3
Holdings
- 3,000,000
Common Stock
[F1]
Footnotes (1)
- [F1]Consists of (i) 1,900,000 shares of common stock acquired by the Reporting Person on the Effective Date of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person, as partial upfront consideration (the "Upfront Payment"), and (ii) 1,100,000 shares of common stock that the Reporting Person became entitled to receive, and acquired the right to acquire, upon the achievement of a development milestone under the License Agreement on 05/18/2026. The Reporting Person is deemed to have acquired beneficial ownership of such shares on the date its right to receive them became fixed. All shares are held of record by, and registered in the name of, the Reporting Person.
Signature
Innovative Cellular Therapeutics Holdings Limited
By: /s/ Lei Xiao
Name: Lei Xiao
Title: Chief Executive Officer|2026-06-18